Read our latest updates & insights

Sorrento Therapeutics announces partner Mabpharm has submitted a New Drug Application for its biosimilar infliximab to the Chinese NMPA.

New study demonstrates noninferiority of Pfizer’s Nivestim® to reference Neupogen®. Additionally, the study demonstrated that those in the biosimilar group reported a shorter median hospitalisation period by two days.

Clover announces it has received approved to enter clinical trials in China with SCB-808, biosimilar etanercept.

Amgen submits BLA for biosimilar rituximab to FDA. 

Amgen and Tanvex file a joint stipulation of dismissal in their filgrastim dispute. The stipulation of dismissal states that parties will bear their own costs and attorney’s fees.

NeuClone announces completion of patient recruitment and dosing in Ph I trials of ustekinumab biosimilar.

Qilu receives Chinese approval for its bevacizumab biosimilar, Ankada®. 

Dong-A Socio Holdings and Meiji Seika announce commencement of Ph I trials of ustekinumab biosimilar.

Lupin releases results of Ph III trials of etanercept biosimilar, reporting similarity with the reference product.

Pfizer receives positive CHMP opinion for its biosimilar adalimumab product.